WO2023118550A1 - Symbiotique destiné à être utilisé dans une méthode de thérapie - Google Patents

Symbiotique destiné à être utilisé dans une méthode de thérapie Download PDF

Info

Publication number
WO2023118550A1
WO2023118550A1 PCT/EP2022/087687 EP2022087687W WO2023118550A1 WO 2023118550 A1 WO2023118550 A1 WO 2023118550A1 EP 2022087687 W EP2022087687 W EP 2022087687W WO 2023118550 A1 WO2023118550 A1 WO 2023118550A1
Authority
WO
WIPO (PCT)
Prior art keywords
synbiotic
vitamin
cfu
lactobacillus
probiotic
Prior art date
Application number
PCT/EP2022/087687
Other languages
German (de)
English (en)
Inventor
Thomas Francis
Original Assignee
AASAYA LifeScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AASAYA LifeScience GmbH filed Critical AASAYA LifeScience GmbH
Publication of WO2023118550A1 publication Critical patent/WO2023118550A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Definitions

  • the invention relates to a synbiotic with the features of independent patent claim 1, a synbiotic for use in a therapy method with the features of independent patent claim 13 and a method with the features of independent patent claim 15.
  • the human microbiome includes numerous microorganisms that have a significant impact on metabolism and human health.
  • the intestinal microbiome is of particular importance, to which numerous other functions are ascribed in addition to the task of food utilization. These functions include the defense against pathogens or the synthesis of vitamins and fatty acids.
  • the microbiome of the gut is sometimes significantly influenced by diet. Influences such as stress or taking medication, especially antibiotics, can also lead to a negative change in the intestinal microbiome and thus cause or promote diseases. Damage to the intestinal microbiome can also be caused by oral vaccinations. It is known from the prior art that in the context of oral vaccinations, pathogenic bacterial strains are used as carriers for orally administered vaccines in order to overcome the physiological tolerance limit in the intestine and to activate the body's immune system or penetration of the vaccine-coupled bacterial cultures through the intestinal wall to allow. On the one hand, this procedure can result in an uncontrolled immune response of the organism and, on the other hand, a sometimes significant damage to the intestinal mucosa as well as a negative change in the intestinal microbiome.
  • the object of the invention is to provide a synbiotic for modulating the human intestinal microbiome, by means of which a composition of the intestinal microbiome of a human organism is improved and/or a deterioration in the composition of the intestinal microbiome of a human organism is prevented.
  • a further object of the invention is to provide a synbiotic by which activation of the human immune system can be achieved in order to improve the effect of drugs, in particular vaccines, administered with the synbiotic, before the synbiotic or after the synbiotic.
  • a synbiotic comprising at least one prebiotic and at least one probiotic, wherein at least one prebiotic is a human milk oligosaccharide (HMO).
  • HMO human milk oligosaccharide
  • a probiotic is generally understood to mean a preparation, mixture of substances or the like which contains one or more living microorganisms which, if taken in sufficient quantities, provide people with a health-promoting benefit.
  • the term probiotic refers to a specific type of microorganism.
  • the wording that at least one probiotic is included means in the present case that at least one type of probiotic microorganism is included.
  • a microorganism unless otherwise stated, means a bacterium.
  • the bacterium is preferably a bacterium with protective and/or health-promoting properties in relation to the intestinal microbiome, particularly preferably a bifidobacterium or a lactic acid bacterium.
  • a prebiotic is generally understood to mean a preparation, mixture of substances or the like which contains one or more, in particular indigestible, substance or substances which have a beneficial effect on the human intestinal microbiome.
  • the beneficial effect can be that a substance serves as a, in particular selective, food source for at least one microorganism, stimulates the growth and/or activity of at least one microorganism or changes the habitat of at least one microorganism in a positive way, in particular with regard to propagation of the microorganism affected.
  • a selective food source is understood to mean a food source that can only be used or metabolized as food by one (health-promoting or protective) microorganism or individual (health-promoting or protective) microorganisms.
  • prebiotic in the context of the present invention refers to one specific substance or a specific mixture of substances.
  • the wording that at least one prebiotic is included means in the present case that at least one prebiotic substance is included.
  • a prebiotic can be a preferably indigestible saccharide (carbohydrate).
  • indigestible refers to the fact that the substance or the prebiotic in question does not reach the intestine, preferably the large intestine, of a person after oral intake, not resorbed, in relation to positive effects (e.g. reproduction and/or growth and/or increase in activity). to achieve bacterial cultures located there.
  • Prebiotics also enable the immune system to be activated and the tolerance limit to trigger an immune response in the human organism to be reduced. As a result, the desired immune response of the organism to an administered vaccine can be favored or strengthened in the course of a vaccination.
  • a synbiotic is generally understood to be a combination of probiotics and prebiotics, which has a positive effect on the health of a human organism.
  • the positive effect can consist, for example, in promoting the growth or activity of health-promoting or protective bacterial strains of the intestinal microbiome and/or in supporting the survival and/or colonization of the probiotic microorganisms supplied by the synbiotic.
  • the concept of a combination does not mean that the prebiotics and probiotics combined in a synbiotic must necessarily be taken or administered at the same time. Simultaneous intake of all components of the synbiotic as well as delayed intake of individual components, in particular the prebiotics and probiotics contained, are conceivable.
  • the time lag between taking the prebiotics of a synbiotic according to the invention and the probiotics of a synbiotic according to the invention can be less than or exactly 15 minutes, preferably less than or exactly 10 minutes, particularly preferably less than or exactly 5 minutes.
  • Human milk oligosaccharides are components of human breast milk and serve as selective nutrition for protective and/or health-promoting intestinal bacteria, in particular bifidobacteria.
  • the growth or multiplication of health-promoting bacterial strains, in particular bifidobacteria can be stimulated.
  • the dominance of health-promoting intestinal bacteria, in particular bifidobacteria and/or Lactic acid bacteria in the human gut microbiome hinder colonization of the gut by pathogenic bacteria.
  • the synbiotic according to the invention combines the positive properties of prebiotics and probiotics with regard to the intestinal microbiome and intestinal health.
  • at least one prebiotic which is a human milk oligosaccharide
  • the life span of at least individual microorganisms (probiotics) supplied via the synbiotic according to the invention can be extended and their growth and activity can be stimulated.
  • the prebiotic contained in the synbiotic according to the invention also enables the immune system to be activated and the tolerance limit for triggering an immune response in the human organism to be reduced.
  • a synbiotic according to the invention thus offers the advantage that the immune system is not activated by pathogenic but by physiologically compatible components (in particular the prebiotics).
  • the medicament can be a vaccine. This results in the advantage of increased tolerability and reduced side effects, while at the same time the drug or vaccination is highly effective.
  • At least one probiotic is a preferably non-pathogenic bifidobacterium and/or that at least one probiotic is a preferably non-pathogenic lactic acid bacterium (lactobacterium).
  • Lactic acid bacteria and bifidobacteria naturally colonize the human intestine, where they have tasks such as supporting and regulating digestion, strengthening the immune system, regulating the pH value in the intestinal environment and increasing antibody production.
  • lactic acid bacteria predominantly colonize the small intestine and bifidobacteria predominantly the large intestine.
  • a dominance of lactic acid and bifidobacteria in the human intestine can prevent excessive colonization of the same by pathogenic bacteria, strengthen the immune system and protect against infectious diseases.
  • the synbiotic according to the invention contains several, in particular at least two, at least three, at least four or at least five, different prebiotics and/or several, in particular at least two, at least three, at least four or at least five probiotics different from one another includes.
  • at least one prebiotic is a saccharide, in particular an indigestible saccharide.
  • all the prebiotics contained in the synbiotic according to the invention, in particular indigestible ones, are saccharides.
  • At least one probiotic is a preferably non-pathogenic lactic acid bacterium and/or that at least one probiotic is a preferably non-pathogenic bifidobacterium. It can also be provided that all the probiotics contained in the synbiotic according to the invention are bacteria from the group of bifidobacteria and lactic acid bacteria.
  • At least one prebiotic is a human milk oligosaccharide from the group 2'-FL (2'-fucosyllactose), LNnT (lacto-N-neotetraose).
  • the human milk oligosaccharides 2'-FL and LNnT can reduce the risk of infectious diseases because they prevent toxins and pathogens from adhering to the intestinal mucosa and reduce inflammatory reactions of the immune system.
  • the synbiotic according to the invention comprises at least two prebiotics, the at least two prebiotics preferably being 2'-FL and LNnt.
  • the inventive Synbiotic includes at least one vitamin in addition to at least one prebiotic and at least one probiotic.
  • Vitamins are organic compounds that are essential for a human organism, but which the human organism cannot synthesize independently or not to a sufficient extent. Accordingly, vitamins must be ingested in sufficient quantities through food. A vitamin deficiency can therefore occur, among other things, as a result of malnutrition and usually has negative health effects on the human organism.
  • a vitamin deficiency can also be caused by negative changes in the intestinal microbiome.
  • Vitamins in particular vitamin A, vitamin D, vitamin E and vitamin K, also contribute to the maintenance and health of mucous membranes, in particular the intestinal mucosa, and thus have a direct effect on the intestinal health of a human organism.
  • Vitamin C is characterized, among other things, by its antioxidant effect.
  • Vitamins B1, B2, B3, B5, B6, B7, B9 and B12 are also of great importance in relation to metabolic functions, digestion and the function of the immune system.
  • the addition of at least one vitamin to the synbiotic according to the invention thus offers the advantage of actively counteracting an existing vitamin deficiency and promoting or preserving the health of the intestinal mucosa and protecting it against pathogenic influences.
  • the synbiotic according to the invention comprises at least 12 vitamins, the at least 12 vitamins preferably being vitamins A, D, E, K, C, B1, B2, B3, B5, B6, B7 and B12. This results in the advantage of an improved supply of vitamins to the human organism.
  • pg to 800 pg in particular 200 pg to 600 pg, preferably 400 pg to 500 pg, particularly preferably 400 pg vitamin A,
  • - 1 pg to 35 pg in particular 1 pg to 15 pg, preferably 1 pg to 5 pg, particularly preferably 3 pg vitamin D, - 1 g to 270 pg, in particular 1 pg to 100 pg, preferably 5 pg to 30 pg, particularly preferably 9 pg vitamin E,
  • pg to 750 pg in particular 1 pg to 300 pg, preferably 10 pg to 50 pg, particularly preferably 30 pg vitamin K,
  • 0.1 mg to 22 mg in particular 0.1 mg to 10 mg, preferably 0.5 mg to 1.5 mg, particularly preferably 1.1 mg vitamin B1,
  • pg to 500 pg in particular 1 pg to 100 pg, preferably 5 pg to 30 pg, particularly preferably 15 pg vitamin B7,
  • the synbiotic according to the invention contains at least one of the vitamins listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more vitamins corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of vitamins to the human organism with regard to the use of the synbiotic according to the invention by an adult .
  • An adult is defined within the scope of the present invention as a person who has reached the age of 11.
  • the synbiotic contains at least one of the vitamins listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more vitamins corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of vitamins to the human organism with regard to the use of the synbiotic according to the invention by an adult .
  • An adult is defined within the scope of the present invention as a person who has reached the age of 11.
  • pg to 20 pg in particular 1 pg to 15 pg, preferably 1 pg to 5 pg, particularly preferably 1 pg vitamin D,
  • pg to 9 pg in particular 1 pg to 8 pg, preferably 2 pg to 7 pg, particularly preferably 5 pg vitamin E,
  • - 0.1 mg to 0.8 mg in particular 0.1 mg to 0.7 mg, preferably 0.1 mg to 0.6 mg, particularly preferably 0.5 mg vitamin B1, - 0.1 mg to 0.9 mg, in particular 0.1 mg to 0.7 mg, preferably 0.1 mg to 0.6 mg, particularly preferably 0.5 mg vitamin B2,
  • 0.1 mg to 4 mg in particular 0.1 mg to 3 mg, preferably 1 mg to 2 mg, particularly preferably 1.5 mg vitamin B5,
  • 0.1 mg to 1 mg in particular 0.1 mg to 0.8 mg, preferably 0.2 mg to 0.6 mg, particularly preferably 0.5 mg vitamin B6,
  • 0.1 pg to 2.5 pg in particular 0.1 pg to 2 pg, preferably 0.1 pg to 1.5 pg, particularly preferably 1 pg of vitamin B12.
  • the synbiotic according to the invention contains at least one of the vitamins listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more vitamins corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of vitamins to the human organism with regard to the use of the synbiotic according to the invention by a child .
  • a child is defined within the scope of the present invention as a person who has not yet reached the age of 11 and preferably has already reached the age of six.
  • 1.54 pg to 38.46 pg in particular 1.54 pg to 30.77 pg, preferably 1.54 pg to 23.08 pg, particularly preferably 15.38 pg of vitamin B12 per 100 g of the synbiotic.
  • the synbiotic contains at least one of the vitamins listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more vitamins according to the amounts given above has proven itself with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of the human organism with vitamins, with regard to the use of the synbiotic according to the invention by a child, proved to be advantageous.
  • a child is defined within the scope of the present invention as a person who has not yet reached the age of 11 and preferably has already reached the age of six.
  • the synbiotic according to the invention comprises at least two different prebiotics and in particular at least one prebiotic is a saccharide from the group FOS (fructooligosaccharide), GOS (galactooligosaccharide), inulin.
  • at least one of at least two prebiotics contained in the synbiotic according to the invention is a saccharide from the group FOS, GOS, inulin.
  • Inulin is a mixture of, in particular indigestible, polysaccharides, which is obtained from plants and can be metabolized in particular by bifidobacteria as a selective food source.
  • a supply of inulin has a positive effect on the growth or multiplication of bifidobacteria in the human intestinal microbiome.
  • Fructooligosaccharides serve as a selective food source for lactic acid bacteria.
  • a supply of FOS has a positive effect on the growth or multiplication of lactic acid bacteria in the human intestinal microbiome.
  • galactooligosaccharides also have a positive effect on the growth or reproduction of health-promoting bacterial strains in the human intestinal microbiome.
  • GOS promotes the growth or multiplication of bifidobacteria and lactic acid bacteria.
  • the growth or multiplication of health-promoting bacterial strains in the human intestinal microbiome is selectively promoted by supplying FOS and/or GOS and/or inulin, whereby an excessive spread of pathogenic bacterial strains in the human intestinal microbiome can be prevented.
  • the synbiotic according to the invention comprises precisely one prebiotic. It can also be provided that the synbiotic according to the invention comprises at least two or exactly two, in particular at least three or exactly three, preferably at least four different prebiotics, in particular all prebiotics from the group FOS, 2'-FL, LNnt, GOS, inulin are selected.
  • the synbiotic according to the invention comprises at least or exactly five prebiotics, the at least or exactly five prebiotics being FOS, 2′-FL, LNnT, GOS and inulin.
  • - 1 mg to 15000 mg in particular 100 mg to 7500 mg, preferably 300 mg to 1000 mg, particularly preferably 700 mg 2'-FL,
  • the synbiotic according to the invention contains at least one of the prebiotics listed above in an amount which is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of the prebiotics already explained and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by an adult.
  • At least one of the following prebiotics is optionally possible, in particular with regard to the use or intake of the synbiotic by an adult, for at least one of the following prebiotics to be included at least in the specified amount or in the specified amount: - 15.38 mg to 230769.23 mg, in particular 7692.31 mg to 153846.15 mg, preferably 15384.62 mg to 30769.23 mg, particularly preferably 23076.92 mg FOS per 100 g of the synbiotic,
  • the synbiotic contains at least one of the prebiotics listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of the prebiotics already explained and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by an adult.
  • - 1 mg to 400 mg in particular 100 mg to 350 mg, preferably 150 mg to 250 mg, particularly preferably 200 mg 2'-FL,
  • - 1 mg to 100 mg in particular 10 mg to 80 mg, preferably 40 mg to 60 mg, particularly preferably 50 mg LNnT, - 1 mg to 400 mg, in particular 100 mg to 350 mg, preferably 150 mg to 250 mg, particularly preferably 200 mg GOS,
  • - 10 mg to 400 mg in particular 100 mg to 350 mg, preferably 150 mg to 250 mg, particularly preferably 200 mg of inulin.
  • the synbiotic according to the invention contains at least one of the prebiotics listed above in an amount which is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the already explained effects and advantages of the respective prebiotics and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by a child.
  • the synbiotic contains at least one of the prebiotics listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the already explained effects and advantages of the respective prebiotics and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by a child.
  • At least one mineral is included, in particular that at least one mineral from the group calcium, magnesium, iron, zinc, manganese, selenium, chromium, molybdenum is included.
  • Minerals are inorganic nutrients that are essential for a human organism, but which it cannot synthesize independently. Accordingly, minerals must be ingested in sufficient quantities through food. Minerals have important tasks in relation to the human organism. For example, they are part of hormones, bones or blood cells, support the transmission of stimuli and serve to activate enzymes. A lack of minerals can have negative effects on the health of the human organism and result in, for example, tiredness, dizziness, skin changes, osteoporosis or a blood deficiency.
  • the addition of at least one mineral to the synbiotic according to the invention thus offers the advantage of being able to actively counteract an acute mineral deficiency or of being able to generally prevent a mineral deficiency.
  • the synbiotic according to the invention comprises at least 8 minerals, the at least 8 minerals preferably being the minerals calcium, magnesium, iron, zinc, manganese, selenium, chromium and molybdenum. This results in the advantage of an improved supply of minerals to the human organism.
  • - 1 pg to 200 pg in particular 20 pg to 100 pg, preferably 40 pg to 60 pg, particularly preferably 55 pg selenium.
  • - 1 pg to 350 pg in particular 10 pg to 200 pg, preferably 30 pg to 100 pg, particularly preferably 50 pg molybdenum.
  • the synbiotic according to the invention contains at least one of the minerals listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more minerals in accordance with the amounts given above has been found to be effective in terms of the effects and advantages of minerals already explained and from the point of view of an adequate supply of minerals to the human organism, in relation to the use of the synbiotic according to the invention by an adult proven beneficial.
  • the synbiotic contains at least one of the minerals listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more minerals corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of minerals already explained and from the point of view of an adequate supply of the human organism with minerals, with regard to the use of the synbiotic according to the invention by an adult .
  • - 1 mg to 1000 mg in particular 400 mg to 1000 mg, preferably 700 mg to 900 mg, particularly preferably 800 mg calcium, - 1 mg to 250 mg, in particular 100 mg to 250 mg, preferably 200 mg to 250 mg, particularly preferably 240 mg magnesium,
  • - 1 pg to 350 pg in particular 10 pg to 200 pg, preferably 30 pg to 100 pg, particularly preferably 50 pg molybdenum.
  • the synbiotic according to the invention contains at least one of the minerals listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more minerals in accordance with the amounts specified above has been found to be effective in terms of the effects and advantages of minerals already explained and from the point of view of an adequate supply of minerals to the human organism, in relation to the use of the synbiotic according to the invention by a child proven beneficial.
  • the synbiotic contains at least one of the minerals listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of one or more minerals corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of minerals already explained and from the point of view of an adequate supply of the human organism with minerals, with regard to the use of the synbiotic according to the invention by a child .
  • At least one probiotic is a bifidobacterium, in particular that at least one probiotic is a bifidobacterium from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve.
  • at least one probiotic comprised by the synbiotic according to the invention is a bifidobacterium from the above-mentioned group of bifidobacteria.
  • bifidobacteria from the above group has proven to be particularly advantageous in order to achieve the advantages described in connection with bifidobacteria by administering the synbiotic according to the invention in a human organism. It can also be provided that all of the probiotics included in the synbiotic according to the invention are bifidobacteria, in particular bifidobacteria from the above-mentioned group of bifidobacteria.
  • At least one probiotic is a lactic acid bacterium
  • at least one probiotic is a lactic acid bacterium from the group Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus.
  • At least one probiotic comprised by the synbiotic according to the invention is a lactic acid bacterium from the above-mentioned group of lactic acid bacteria.
  • the use of one or more lactic acid bacteria from the above Group has proven to be particularly advantageous in order to achieve the advantages described in connection with lactic acid bacteria by administering the synbiotic according to the invention in a human organism.
  • all probiotics comprised by the synbiotic according to the invention are lactic acid bacteria, in particular lactic acid bacteria from the above-mentioned group of lactic acid bacteria.
  • probiotics comprised by the synbiotic from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acid ophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus are selected.
  • the use of at least Bifidobacterium breve and Lactobacillus casei and/or at least Lactobacillus bulgaricus, Bifidobacterium lactis and Streptococcus thermophilus and/or at least Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacterium bifidum results in at least advantages with regard to the prevention of surgical infections and complications .
  • the use of at least Lactobacillus paracasei and Lactobacillus plantarum also proves to be advantageous in this respect.
  • a use of at least Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum and Lactobacillus bulgaricus proves at least Beneficial in relation to the treatment of non-alcoholic fatty liver.
  • the use of at least Lactobacillus plantarum is at least advantageous with regard to the prevention of sepsis, particularly in children.
  • the use of at least Lactobacillus gasseri proves at least beneficial in liver disease.
  • the use of at least Lactobacillus rhamnosus GG offers benefits in the prevention of atopic dermatitis.
  • At least Bifidobacterium infantis In the treatment of atopic dermatitis, the use of at least Bifidobacterium infantis has proven beneficial.
  • a combination of at least Bifidobacterium longum and Lactobacillus helveticus may have a beneficial effect on stress-related symptoms.
  • Use of at least Bifidobacterium adolescentis is at least beneficial in treating constipation.
  • a use of at least Lactobacillus helveticus is at least advantageous with regard to nutrient absorption in the human intestine.
  • Use of at least Lactobacillus johnsonii and/or Lactobacillus brevis offers benefits in terms of prevention and treatment of inflammation.
  • Using at least Lactobacillus reuterii offers the advantage of an antimicrobial and antifungal effect.
  • the synbiotic according to the invention comprises exactly one probiotic. It can also be provided that the synbiotic according to the invention comprises at least two or exactly two, in particular at least three or exactly three, preferably at least 10, preferably at least 15, particularly preferably at least 20 probiotics, with the probiotics preferably at least partially, in particular all, from the Group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lac tobacillus gasseri, Lactobacillus johnsonii, Lactobacillus re
  • - 1-10 1 CFU to 2 10 15 CFU in particular 1 -10 5 CFU to 2 10 12 CFU, preferably, 1 -10 8 CFU to 2 10 10 CFU, particularly preferably 2.4- 10 9 CFU B.
  • bifidum - 1 -10 1 CFU to 210 15 CFU, in particular 1 ⁇ 10 5 CFU to 210 12 CFU, preferably, 1 ⁇ 10 8 CFU to 21O 10 CFU, particularly preferably 2.410® CFU B. longum,
  • - 1-10 1 CFU to 210 15 CFU in particular 1 -10 5 CFU to 210 12 CFU, preferably, 1 -10 8 CFU to 2'10 1 ° CFU, particularly preferably 2.4- 10® CFU L. fermentum
  • - 1-10 1 cfu to 2 10 16 cfu in particular 1 -10 5 cfu to 2 10 12 cfu, preferably, 1 -10 9 cfu to 2 10 11 cfu, particularly preferably 1 ⁇ 10 10 cfu L. plantarum
  • the abbreviation "B.” used in the above listing stands for Bifidobacterium.
  • the abbreviation “L.” used in the above listing stands for Lactobacillus.
  • the bacterium Lactobacillus bulgaricus is also known as Lactobacillus delbruecki subspecies bulgaricus.
  • the bacterium Lactobacillus paracasei is also known as Lactobacillus paracasei subspecies paracasei. All quantities are given in colony forming units (CFU).
  • CFU colony forming units
  • the synbiotic contains at least one of the probiotics listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case.
  • a dosage of a probiotic or several probiotics corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of probiotics already explained.
  • At least one prebiotic, preferably at least two prebiotics, particularly preferably all prebiotics, of the synbiotic are contained in a prebiotic mixture and/or that at least one probiotic, preferably at least two probiotics, particularly preferably all, probiotics of the synbiotic contained in a probiotic mixture.
  • the prebiotic mixture and the probiotic mixture can be used or taken separately, in particular at different times, or together, in particular simultaneously.
  • all prebiotics of the synbiotic according to the invention form a prebiotic mixture and all probiotics of the synbiotic according to the invention form a probiotic mixture, with the prebiotic mixture and the probiotic mixture being present separately from one another and being used or taken independently of one another (at different times) or at the same time can.
  • the prebiotic mixture comprises at least one prebiotic and the probiotic mixture comprises at least one probiotic.
  • the prebiotic mixture can include other components such as at least one vitamin and/or at least one mineral and/or at least one drug.
  • the probiotic mixture can also comprise other components such as at least one medicinal product.
  • the feature described above relates in particular to a separation of individual and/or all prebiotics and probiotics comprised by the synbiotic from one another in order to ensure independent intake or to be able to use the prebiotics and probiotics of the synbiotic according to the invention.
  • the prebiotic mixture is taken or used before the probiotic mixture. It is also conceivable that there is a time lag between the intake or use of the prebiotic mixture and the probiotic mixture.
  • the time lag between taking or using the prebiotic mixture and the probiotic mixture can be between 0.5 minutes and 15 minutes, in particular between 1 minute and 10 minutes, preferably between 2 minutes and 10 minutes, particularly preferably between 3 minutes and 5 minutes.
  • a preparatory effect in particular of the prebiotics, can first be achieved before the remaining components of the synbiotic are added. This can increase the effectiveness of the synbiotic and/or the effectiveness of a drug administered with the synbiotic.
  • the preparatory effect can consist, for example, in stimulating or activating the immune system.
  • activation of the immune system by the prebiotic mixture can first be awaited and only then can the probiotic mixture be administered as a carrier of a vaccine and thus together, in particular at the same time, with the vaccine.
  • the immune response of the human organism to the vaccine can be increased and thus a higher effectiveness of the vaccination can be achieved.
  • the synbiotic is not used as part of a vaccination, but only to modulate the intestinal microbiome, it can also be provided that the prebiotic mixture and the probiotic mixture are used or taken at the same time.
  • the synbiotic according to the invention can thus be handled optimally.
  • a simultaneous intake of all components of the synbiotic according to the invention is not excluded from the present invention, even in the context of a vaccination.
  • At least one vitamin in addition to at least one prebiotic, at least one vitamin, in particular all vitamins of a synbiotic according to the invention, and/or at least one mineral, in particular all minerals of a synbiotic according to the invention, is/are included in the prebiotic mixture.
  • at least one drug preferably at least one vaccine, is comprised by the synbiotic according to the invention.
  • At least one vaccine can be a live vaccine, an inactivated vaccine, a gene-based vaccine, in particular a DNA vaccine or a vector vaccine or a protein-based vaccine or an RNA vaccine (preferably an mRNA vaccine).
  • the vaccine can be a monovalent or polyvalent vaccine.
  • the vaccine can be a coronavirus vaccine, preferably a Covid-19 vaccine (SARS-CoV-2 vaccine). It is also conceivable that the vaccine is an influenza vaccine.
  • At least one vaccine or at least one vaccine component is coupled with at least one prebiotic, in particular molecularly.
  • at least one vaccine or at least one vaccine component is coupled with a prebiotic from the group inulin, FOS, GOS, preferably with inulin.
  • at least one vaccine or at least one vaccine component is coupled to functional groups or non-polar carbon-hydrogen (C-H) compounds of at least one prebiotic.
  • different components of a vaccine are coupled to different components of the synbiotic according to the invention. So it is conceivable that at least one vaccine component of a vaccine is coupled to at least one prebiotic and at least one other vaccine component of the vaccine is coupled to at least one probiotic. Also different components of a vaccine can be coupled to different prebiotics or different probiotics of the synbiotic according to the invention.
  • the synbiotic according to the invention is contained in at least one capsule.
  • the capsule has several, in particular at least two, chambers, with at least one prebiotic mixture being contained in a first chamber and at least one probiotic mixture being contained in a second chamber.
  • the capsule may be an enteric-coated sustained-release capsule.
  • the capsule can be provided with an enteric coating.
  • the coating can be made from a synthetic polymer, in particular a synthetic polymer from the group consisting of polymethacrylates, vinyl acetate-vinylpyrrolidone copolymers, and polyvinyl acetate phthalates.
  • the coating can also be made of a semi-synthetic polymer, in particular a cellulose derivative.
  • a semi-synthetic polymer in particular a cellulose derivative.
  • the synbiotic according to the invention is contained in two separate capsules, with a first capsule containing at least one prebiotic mixture and a second capsule containing at least one probiotic mixture. Both capsules can be designed identically or differently, in particular in accordance with the above statements with regard to the possible embodiments of a capsule.
  • the prebiotics and/or the probiotics of the synbiotic according to the invention are at least partially connected to at least one substrate, in particular at least one substrate being a solid or a fluid (liquid or gaseous).
  • the prebiotics and the probiotics are at least partially connected to the same substrate.
  • the prebiotics are associated with at least one first substrate and the probiotics are associated with at least one second substrate, the first substrate being different from the second substrate.
  • Each substrate can be a solid or a fluid, in particular a liquid.
  • the prebiotics and / or the probiotics of the synbiotic according to the invention are at least partially dissolved in a fluid, in particular in a liquid or a gel, or form an emulsion or suspension with the fluid and thus by a ingestion of the fluid can be administered.
  • the fluid can be a fluid containing sugar or sweetener.
  • the solid or mixture of solids can be a conventional foodstuff, preferably one containing sugar or sweeteners, in particular a muesli bar, a candy, a lollipop or the like.
  • Administration or intake or use of the synbiotic or individual components of the synbiotic, in particular the prebiotics and/or probiotics, in connection with milk, yoghurt and/or dairy products is also conceivable within the scope of the invention.
  • the combination of the synbiotic according to the invention or parts of the synbiotic according to the invention with foodstuffs or sweeteners has the advantage that intake, in particular for children, is made considerably more pleasant and thus simplified.
  • synbiotic can be ingested or used by inhalation.
  • the synbiotic according to the invention or parts thereof can be administered or can be administered in the form of a spray.
  • Dermal, intradermal or intracavitary administration can also be provided.
  • Other modes of administration are not excluded from the scope of the present invention.
  • the synbiotic according to the invention is in tablet form. It is conceivable here that all the components of a synbiotic according to the invention are contained in one tablet. Provision can also be made for individual components of a synbiotic according to the invention to be contained in separate tablets. It can be provided that at least all prebiotics of a synbiotic according to the invention, in particular also all vitamins and/or minerals of a synbiotic according to the invention, are included in a first tablet and at least all probiotics of a synbiotic according to the invention are included in a second tablet. In addition to the synbiotic or parts of the synbiotic, a tablet can contain other substances such as fillers (e.g.
  • a tablet can be designed as a film tablet, which results in the advantage of simplified administration.
  • a synbiotic according to the invention is used in a therapy method.
  • the therapy method is at least one of the following:
  • Therapeutic methods for the prophylaxis and/or treatment of diseases of the central nervous system and/or the peripheral nervous system in particular depression, anxiety, fatigue, long/post-COVID syndrome and/or brain diseases
  • Therapeutic methods for the prophylaxis and/or treatment of allergies and/or autoimmune diseases in particular type 1 diabetes mellitus or rare diseases
  • Treatment methods to support organ system and organ health in particular heart health, brain health, metabolic health, liver health, kidney health, lung health, skin health and/or human genetics health.
  • a synbiotic according to the invention in a therapeutic method for the prophylaxis and/or treatment of infections, it can be provided that it is a therapeutic method for the prophylaxis and/or treatment of coronavirus infections and/or diseases.
  • it is conceivable that it is a therapeutic method for the prophylaxis and/or treatment of SARS-CoV-2 infections and/or COVID-19 diseases.
  • a therapeutic method for the prophylaxis and/or treatment of influenza virus infections and/or diseases is involved.
  • the therapeutic method is a vaccination, with the vaccine being a component of the synbiotic according to the invention and/or at least with parts of the synbiotic according to the invention is administered together.
  • Co-administration does not necessarily mean simultaneous administration. Even a small time lag, in particular a time lag of less than 5 minutes, preferably less than 3 minutes, particularly preferably less than 1 minute, between the administration of the vaccine and the administration of the synbiotic according to the invention or parts thereof, is present as a common Administration understood.
  • a method according to the invention for the production of a synbiotic in particular designed according to one of claims 1 to 11, wherein at least the following steps are preferably carried out in the order given: a) determination of at least a first prebiotic amount of a first prebiotic, in particular by weighing, with at least the first prebiotic being a human milk oligosaccharide (HMO), b) determining at least a first probiotic quantity of a first probiotic, in particular by counting colony-forming units.
  • HMO human milk oligosaccharide
  • amount refers to a weight.
  • prebiotic amount means an amount by weight of a prebiotic.
  • a prebiotic amount may be 10 mg of a prebiotic such as FOS, GOS, 2'-FL, LNnT, or inulin.
  • the term “quantity” refers to a number.
  • the term probiotic amount means a certain number of colony forming units (CFU) of a probiotic, in particular a bifidobacterium or lactic acid bacterium.
  • a probiotic amount can be 2 10 9 CFU of a bifidobacterium (e.g. Bifidobacterium bifidum).
  • the following method step is additionally carried out: i. preparing a synbiotic mixture by mixing at least the first amount of prebiotic and the first amount of probiotic.
  • synbiotic mixture which contains all the components of the synbiotic
  • all the components of the synbiotic i.e. preferably at least all the prebiotics, vitamins, minerals, probiotics and drugs contained in the synbiotic according to the invention, are mixed with one another in any order to create the synbiotic to make a mixture.
  • At least the first prebiotic is one from the group 2'-FL, LNnT.
  • At least the first probiotic is a bifidobacterium or a lactic acid bacterium.
  • at least the first probiotic is a bacterium from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lac tobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum
  • a probiotic is a bacterium (e.g. bifidobacterium or lactic acid bacterium) does not represent a quantity. In other words, it is a statement of the type of microorganism in question and not a statement of a quantity.
  • step a Determination of at least a second prebiotic quantity of a second prebiotic different from the first, in particular at least the second prebiotic being a saccharide, preferably a saccharide from the group 2'-FL, LNnT, FOS, GOS, inulin, particularly preferably a saccharide from the group FOS, GOS, inulin, is, iii.
  • Determination of at least a first vitamin quantity of a first vitamin in particular by weighing, with at least the first vitamin preferably being one from the group consisting of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12 is, iv.
  • Determination of at least a first mineral amount of a first mineral in particular by weighing, with at least the first mineral preferably being one from the group calcium, magnesium, iron, zinc, manganese, selenium, chromium, molybdenum.
  • step iv. for at least 4, preferably at least 6, particularly preferably at least or exactly 8, preferably different, minerals is carried out.
  • step ii. for exactly one prebiotic in particular for at least two or exactly two, preferably for at least three or exactly three, preferably for at least four or exactly 4, in particular different prebiotics.
  • steps ii. exactly one or at least one, in particular at least two or exactly two, preferably at least 3 or exactly three, preferably at least or exactly 4 amounts of prebiotics can be determined, preferably by weighing, with all prebiotics contained in the synbiotic being different from one another. In combination with the first amount of prebiotics determined in step a), this results in a total of at least two or exactly two, at least three or exactly three, at least four or exactly four, at least five or exactly five amounts of different prebiotics.
  • step b the following method step is additionally carried out: v. Determination of at least a second probiotic amount of a second probiotic different from the first.
  • step v. for exactly one probiotic in particular for at least two or exactly two, preferably at least three or exactly three, preferably at least 9, particularly preferably at least or exactly 19, preferably different, probiotics is carried out.
  • step v. exactly one or at least one, in particular at least two or exactly two, preferably at least three or exactly three, preferably at least 9, particularly preferably at least or exactly 19, amounts of probiotics, preferably by counting colony-forming units, are determined, with all probiotics contained in the synbiotic are different from each other.
  • step b) In combination with the first amount of probiotics determined in step b), this results in a total of at least two or exactly two, at least three or exactly three, at least four or exactly four, at least ten, at least twenty or exactly twenty amounts of different probiotics. It is also optionally possible within the scope of the invention that, in particular after steps a) and b), at least the following method step is additionally carried out: vi. Determination of at least a first drug quantity of a first drug, in particular by weighing, with at least the first drug preferably being a vaccine.
  • At least one of the following method steps is additionally carried out: vii. Preparation of a prebiotic mixture by mixing the first amount of prebiotics with at least a second amount of prebiotics and/or at least one amount of vitamins and/or at least one amount of minerals and/or at least one amount of drug, viii. Preparation of a probiotic mixture by mixing the first amount of probiotics with at least a second amount of probiotics and/or at least one amount of drug.
  • the prebiotic mixture can be produced by mixing at least all of the prebiotics contained in the synbiotic or the corresponding amounts of prebiotics. It is also conceivable that the probiotic mixture is produced by mixing at least all of the probiotics contained in the synbiotic or the corresponding amounts of probiotics.
  • step vii. for at least 4, in particular at least or exactly 5, preferably different, prebiotics or amounts of prebiotics is carried out and/or that step viii. for at least 10, in particular at least or exactly 20, preferably different, probiotics or probiotic amounts is carried out.
  • step vii. at least 4, in particular at least 5 or exactly 5 amounts of prebiotics are mixed to form a prebiotic mixture.
  • step viii. at least 10, in particular at least or exactly 20 amounts of probiotics are mixed to form a probiotic mixture.
  • a probiotic mixture is conceivable in this context. It is also conceivable within the scope of the invention that, in particular after steps a) and b), preferably as the last method step, the following method step is additionally carried out: ix. Making a synbiotic blend by mixing a prebiotic blend and a probiotic blend.
  • FIG. 7 shows a method according to the invention for the production of a synbiotic.
  • the capsule has a first chamber 7.1 and a second chamber 7.2, with a first prebiotic 2.1 or a prebiotic mixture 1.1 being contained in the first chamber 7.1 and a first probiotic 3.1 or a probiotic mixture 1.2 being contained in the second chamber 7.2.
  • the first prebiotic 2.1 is a human milk oligosaccharide from the group 2'FL, LNnt.
  • the prebiotic mixture comprises only the first prebiotic 2.1 and the probiotic mixture in the present case comprises only the first probiotic 3.1.
  • the 2 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 being contained in a capsule 7 .
  • the capsule 7 has a first chamber 7.1 and a second chamber 7.2, with a prebiotic mixture 1.1 being contained in the first chamber 7.1 and a probiotic mixture 1.2 being contained in the second chamber 7.2.
  • the chambers 7.1, 7.2 are spatially separated from one another by a partition.
  • the capsule 7 is designed as a capsule 7 that is resistant to gastric juice.
  • the prebiotic mixture 1.1 comprises several different prebiotics 2.
  • the prebiotic mixture 1.1 comprises at least a first prebiotic 2.1, a second prebiotic 2.2 and a third prebiotic 2.3, with at least the first prebiotic 2.1 being a saccharide, in particular a saccharide on the group 2'-FL , LNnT, FOG, GOS, inulin, is.
  • the prebiotic mixture 1.1 comprises at least one vitamin 4 and at least one mineral 5.
  • the at least one vitamin 4 is a vitamin from the group of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, Vitamin B5, Vitamin B6, Vitamin B7, Vitamin B9, Vitamin B12.
  • the at least one mineral 5 is a mineral 5 from the group consisting of calcium, magnesium, iron, zinc, manganese, selenium, chromium and molybdenum.
  • the probiotic mixture 1.2 comprises several different probiotics 3. In the present case, the probiotic mixture 1.2 comprises at least a first probiotic 3.1 and a second probiotic 3.2, the first probiotic 3.1 being a lactic acid bacterium and the second probiotic 3.2 being a bifidobacterium.
  • Fig. 3 shows a simplified representation of a synbiotic 1 according to the invention.
  • the synbiotic 1 comprises all components of the synbiotic 1 shown in FIG in this case a vaccine.
  • FIG. 4 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 corresponding to the synbiotic 1 shown in FIG. 3 with regard to its composition.
  • the capsule 7 does not have a partition.
  • the prebiotic mixture 1.1 and the probiotic mixture 1.2 are not present separately, but rather all the components of the synbiotic 1 are mixed together, so that a synbiotic mixture 1.3 is present.
  • FIG. 5 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 corresponding to that shown in FIG. 3 with regard to its composition Synbiotic 1 corresponds.
  • the prebiotic mixture 1.1 and the probiotic mixture 1.2 are present separately such that the prebiotic mixture 1.1 and the probiotic mixture 1.2 can be handled independently of one another and thus, for example, can be taken at different times.
  • the prebiotic mixture 1.1 is contained in a first capsule 7 and the probiotic mixture 1.2 is contained in a second capsule 7. Both capsules 7 are designed as capsules 7 that are resistant to gastric juice.
  • the substrate 8 is designed as a liquid in which the prebiotics and the probiotics are dissolved or with which the prebiotics and the probiotics form an emulsion or suspension.
  • the substrate 8 is a liquid containing a sweetener.
  • Fig. 7 shows schematically a method 100 according to the invention for the production of a synbiotic 1, wherein at least the following steps are preferably carried out in the order given: a) Determination (110) of at least a first prebiotic amount of a first prebiotic (2.1), in particular by weighing, wherein at least the first prebiotic (2.1) is a human milk oligosaccharide (HMO), b) determining (120) at least a first probiotic quantity of a first probiotic (3.1), in particular by counting colony-forming units.
  • HMO human milk oligosaccharide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un symbiotique (1) comprenant au moins un prébiotique (2) et au moins un probiotique (3), au moins le prébiotique étant un oligosaccharide de lait humain (HMO).
PCT/EP2022/087687 2021-12-23 2022-12-23 Symbiotique destiné à être utilisé dans une méthode de thérapie WO2023118550A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102021134539.1 2021-12-23
DE102021134539.1A DE102021134539A1 (de) 2021-12-23 2021-12-23 Synbiotikum zur Anwendung in einem Therapieverfahren

Publications (1)

Publication Number Publication Date
WO2023118550A1 true WO2023118550A1 (fr) 2023-06-29

Family

ID=84980976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/087687 WO2023118550A1 (fr) 2021-12-23 2022-12-23 Symbiotique destiné à être utilisé dans une méthode de thérapie

Country Status (2)

Country Link
DE (1) DE102021134539A1 (fr)
WO (1) WO2023118550A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822500A1 (fr) * 2010-12-31 2012-07-05 Abbott Laboratories Oligosaccharides de lait humain pour favoriser la croissance de bacteries benefiques
WO2015071403A1 (fr) * 2013-11-15 2015-05-21 Nestec S.A. Compositions destinée à la prévention ou au traitement de l'entérocolite nécrosante chez les nourrissons et les jeunes enfants
EP2525811B1 (fr) * 2010-01-19 2016-03-16 Abbott Laboratories Une composition comprenant du lactobacillus rhamnosus hn001 et des prébiotiques pour le traitement des maladies pulmonaires allergiques
CN112998276A (zh) * 2021-02-01 2021-06-22 天津科技大学 一种预防益生元过量摄入导致腹泻、肠漏、脓毒症的合生元复方制剂、制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957148B2 (en) 2015-12-15 2024-04-16 Societe Des Produits Nestle S.A. Mixture of human milk oligosaccharides(HMOs)
CN105532883A (zh) 2015-12-21 2016-05-04 海普诺凯营养品有限公司 一种婴幼儿用配方羊奶粉及其制备方法
MX2018008834A (es) 2016-01-26 2019-01-31 Nestec Sa Composiciones con oligosacáridos específicos para prevenir la obesidad más adelante en la vida o comorbilidades relacionadas mediante el incremento de la producción colónica de scfa y/o el incremento de la secreción de glp-1.
WO2019031961A1 (fr) 2017-08-11 2019-02-14 N.V. Nutricia Oligosaccharide de lait humain pour améliorer la condition physique immunitaire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525811B1 (fr) * 2010-01-19 2016-03-16 Abbott Laboratories Une composition comprenant du lactobacillus rhamnosus hn001 et des prébiotiques pour le traitement des maladies pulmonaires allergiques
CA2822500A1 (fr) * 2010-12-31 2012-07-05 Abbott Laboratories Oligosaccharides de lait humain pour favoriser la croissance de bacteries benefiques
WO2015071403A1 (fr) * 2013-11-15 2015-05-21 Nestec S.A. Compositions destinée à la prévention ou au traitement de l'entérocolite nécrosante chez les nourrissons et les jeunes enfants
CN112998276A (zh) * 2021-02-01 2021-06-22 天津科技大学 一种预防益生元过量摄入导致腹泻、肠漏、脓毒症的合生元复方制剂、制备方法和应用

Also Published As

Publication number Publication date
DE102021134539A1 (de) 2023-06-29

Similar Documents

Publication Publication Date Title
DE69936740T2 (de) Oligosaccharide und Probiotica enthaltendes Präparat
DE502007010071C5 (de) Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
US6544568B2 (en) Symbiotic functional food containing lactic acid bacteria
DE60107544T2 (de) Kohlenhydratformulierung (praebiotisches adjuvans) zur steigerung der immunantwort
DE60122570T2 (de) Nahrungszusammensetzung für immunerkrankung
DE60307191T2 (de) Bakterien der Gattung Bifidobacterium longum und Bakterien enthaltende Zusammensetzung
DE60125529T2 (de) MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN
DE10206995B4 (de) Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
AT407008B (de) Formulierungen mit probiotisch wirksamen mikroorganismen
EP2228067B1 (fr) Composition probiotique et son utilisation
AU2016315268B2 (en) Methods and compositions using Bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances
CN109069555A (zh) 面向新生儿的用于改善脑功能的组合物
DE202010008308U1 (de) Zusammensetzung zur nutritiven Ergänzung oder Behandlung bei Harnwegsinfekten und/oder bakteriellen Entzündungen der Schleimhäute
EP2353600A1 (fr) Moyen pour l'application en cas de manque en lactase et d'intolérance au lactose
EP1952703B1 (fr) Produit contenant des microorganismes probiotiques vivants
WO1997016077A1 (fr) Formulations a effet probiotique
CN106852938A (zh) 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
JP2005013211A (ja) 乳酸菌含有食品組成物
DE202018004506U1 (de) Zubereitung einer innovativen BioNaturjogurt-Rezeptur ohne Zuckerzusatz als Basis auch für signifikant zuckerreduzierte Fruchtjogurts
DE102008059070B4 (de) Zusammensetzung zur therapeutischen oder prophylaktischen Behandlung von Durchfallerkrankungen und/oder zur Aufrechterhaltung und/oder Wiederherstellung der natürlichen Darmflora, Dosiereinheit, Verpackungseinheit und Verwendung der Zusammensetzung
EP3556226B1 (fr) Synbiotiques complexes destinés au développement d'un microbiote saine
WO2023118550A1 (fr) Symbiotique destiné à être utilisé dans une méthode de thérapie
DE202020002846U1 (de) Zubereitung einer innovativen Mehrkomponenten-Pulvermischung mit synbiotisch verstärkter Gesamt-Wirkung
CN106974940B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
AT412050B (de) Fermentiertes milchprodukt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22843813

Country of ref document: EP

Kind code of ref document: A1